Degrasyn (WP1130) 856243-80-6
Product Description
.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}
Molecular Weight:
384.27 Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).
Biological Activity
In addition to inducing rapid down-regulation of Bcr/Abl without
affecting Bcr or c-Abl, WP1130 also regulates the stability of Jak2 and
c-Myc without affecting other kinases (HER1, HER2, c-Kit, FAK, ERK1,
ERK2, Akt, Btk, Src and Src-related kinases) or transcription factors
(wild-type p53, STAT1, STAT3, STAT5, c-Jun, NF-κB, and Max). Unlike
adaphostin and Trisenox, WP1130 induces down-regulation of Bcr/Abl
within 60 minutes. WP1130 is more effective in inducing Apoptosis of
myeloid and lymphoid tumor cells with IC50 of ~0.5-2.5 μM compared with
normal CD34+ hematopoietic precursors, dermal fibroblasts, or
endothelial cells with IC50 of ~5-10 μM.
WP1130 (5 μM) specifically and
rapidly down-regulates both wild-type and T315I mutant Bcr/Abl protein
without affecting bcr/abl gene expression or engaging the proteasomal
degradation pathway in chronic myelogenous leukemia (CML) cells,
accompanied by induction of apoptosis. WP1130 is more effective in
reducing leukemic cell colony formation compared with normal progenitor
cells, and effective against primary leukemic cells harboring the T315I
mutation.
WP1130 induces rapid proteasomal-dependent
degradation of c-Myc protein in MM-1 multiple myeloma and Other tumor
cell lines, correlated with tumor growth inhibition. Unlike AG490, WP1130 acts as a partly selective deubiquitinase (DUB)
inhibitor to induce a rapid and marked accumulation of polyubiquitinated
(K48/K63-linked) Proteins into juxtanuclear aggresomes without
affecting proteasome activity. WP1130 (5 μM) directly inhibits DUB
activity of USP9x, USP5, USP14, UCH-L1, and UCH37, but not UCH-L3,
resulting in downregulation of antiapoptotic and upregulation of
proapoptotic proteins, such as MCL-1 and p53.
Administration of WP1130 inhibits the growth of K562 tumors as well as
both wildtype Bcr/Abl and T315I mutant Bcr/Abl-expressing BaF/3 cells
transplanted into nude mice. Consistent with the
down-regulation of c-Myc, WP1130 displays potent inhibitory activity
against A375 melanoma tumors established in nude mice.
Protocol(Only for Reference)
Cell Assay: [1]
Animal Study: [1]
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Chemical Information
Molarity Calculator
Dilution Calculator
Molecular Weight Calculator
Contact us if you need more details on 856243-80-6. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Degrasyn 856243-80-6、WP1130 856243-80-6. If these products fail to match your need, please contact us and we would like to provide relevant information.
Molecular Weight:
384.27 Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).
Biological Activity
In addition to inducing rapid down-regulation of Bcr/Abl without
affecting Bcr or c-Abl, WP1130 also regulates the stability of Jak2 and
c-Myc without affecting other kinases (HER1, HER2, c-Kit, FAK, ERK1,
ERK2, Akt, Btk, Src and Src-related kinases) or transcription factors
(wild-type p53, STAT1, STAT3, STAT5, c-Jun, NF-κB, and Max). Unlike
adaphostin and Trisenox, WP1130 induces down-regulation of Bcr/Abl
within 60 minutes. WP1130 is more effective in inducing Apoptosis of
myeloid and lymphoid tumor cells with IC50 of ~0.5-2.5 μM compared with
normal CD34+ hematopoietic precursors, dermal fibroblasts, or
endothelial cells with IC50 of ~5-10 μM.
WP1130 (5 μM) specifically and
rapidly down-regulates both wild-type and T315I mutant Bcr/Abl protein
without affecting bcr/abl gene expression or engaging the proteasomal
degradation pathway in chronic myelogenous leukemia (CML) cells,
accompanied by induction of apoptosis. WP1130 is more effective in
reducing leukemic cell colony formation compared with normal progenitor
cells, and effective against primary leukemic cells harboring the T315I
mutation.
WP1130 induces rapid proteasomal-dependent
degradation of c-Myc protein in MM-1 multiple myeloma and Other tumor
cell lines, correlated with tumor growth inhibition. Unlike AG490, WP1130 acts as a partly selective deubiquitinase (DUB)
inhibitor to induce a rapid and marked accumulation of polyubiquitinated
(K48/K63-linked) Proteins into juxtanuclear aggresomes without
affecting proteasome activity. WP1130 (5 μM) directly inhibits DUB
activity of USP9x, USP5, USP14, UCH-L1, and UCH37, but not UCH-L3,
resulting in downregulation of antiapoptotic and upregulation of
proapoptotic proteins, such as MCL-1 and p53.
Administration of WP1130 inhibits the growth of K562 tumors as well as
both wildtype Bcr/Abl and T315I mutant Bcr/Abl-expressing BaF/3 cells
transplanted into nude mice. Consistent with the
down-regulation of c-Myc, WP1130 displays potent inhibitory activity
against A375 melanoma tumors established in nude mice.
Protocol(Only for Reference)
Cell Assay: [1]
Cell lines | BV173, BV173R, K562, and BaF/3 |
---|---|
Concentrations | Dissolved in DMSO, final concentrations ~10 μM |
Incubation Time | 72 hours |
Method | Cells are treated with increasing concentrations of WP1130 (0.08-10 μM) in 96-well plates. Plates are incubated at 37 °C for 72 hours, after which 20 μL of MTT reagent is added, and the plates are incubated at 37 °C for another 2 hours. Cells are lysed with 100 μL lysis buffer (20% sodium dodecyl sulfate [SDS] in 50% N, N-dimethylformamide adjusted to pH 4.7 with 80% acetic acid and 1 M hydrochloric acid; final concentration of acetic acid is 2.5% and hydrochloric acid is 2.5%) and incubated for 6 hours. The optical density of each sample at 570 nm is determined with a SPECTRA MAX M2 plate reader. |
Animal Study: [1]
Animal Models | Swiss Nu/Nu mice transplanted with K562 tumor cells, BaF/3wt cells, or BaF/3/T315I cells |
---|---|
Formulation | Formulated in solution of 1:1 dimethylsulfoxide to polyethylene glycol 300 |
Dosages | ~40 mg/kg every other day |
Administration | Injected intraperitoneally |
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species | Baboon | Dog | Monkey | Rabbit | Guinea pig | Rat | Hamster | Mouse |
Weight (kg) | 12 | 10 | 3 | 1.8 | 0.4 | 0.15 | 0.08 | 0.02 |
Body Surface Area (m2) | 0.6 | 0.5 | 0.24 | 0.15 | 0.05 | 0.025 | 0.02 | 0.007 |
Km factor | 20 | 20 | 12 | 12 | 8 | 6 | 5 | 3 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Rat dose (mg/kg) = mouse dose (22.4 mg/kg) × | mouse Km(3) | = 11.2 mg/kg |
rat Km(6) |
Chemical Information
Molecular Weight (MW) | 384.27 |
---|---|
Formula | C19H18BrN3O |
CAS No. | 856243-80-6 |
Storage | 3 years -20℃Powder |
---|---|
6 months-80℃in solvent (DMSO, water, etc.) | |
Synonyms | |
Solubility (25°C) * | In vitro | DMSO | 77 mg/mL (200.37 mM) |
---|---|---|---|
Water | <1 mg/mL ( | ||
Ethanol | 18 mg/mL (46.84 mM) | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Chemical Name | (S,E)-3-(6-bromopyridin-2-yl)-2-cyano-N-(1-phenylbutyl)acrylamide |
---|
Molarity Calculator
Dilution Calculator
Molecular Weight Calculator
Contact us if you need more details on 856243-80-6. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Degrasyn 856243-80-6、WP1130 856243-80-6. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : Angiogenesis > Bcr-Abl Inhibitor
Other Products
Hot Products
Astragaloside AChlortetracycline HCl 64-72-2Paclitaxel 33069-62-4Dexamethasone Acetate 1177-87-3Dinaciclib (SCH727965) 779353-01-4CHIR-124 405168-58-3Ro3280 1062243-51-9TAME 901-47-3CCG-1423 285986-88-110058-F4 403811-55-2Dabigatran (BIBR 953) 211914-51-1H 89 2HCl 130964-39-5T0901317 293754-55-9Aprepitant 170729-80-3Turofexorate Isopropyl (XL335) 629664-81-9BMS-378806 357263-13-9